How many stocks does HHLR ADVISORS, LTD. own?

As of Q4 2025, HHLR ADVISORS, LTD. holds 33 positions in their 13F portfolio.

What is HHLR ADVISORS, LTD.'s largest holding?

PDD at 39.2% of portfolio, worth $1.2B.

What is HHLR ADVISORS, LTD.'s total portfolio value?

$3.1B as of Q4 2025, tracked across 33 holdings.

Is HHLR ADVISORS, LTD. a hedge fund?

HHLR ADVISORS, LTD. is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does HHLR ADVISORS, LTD. report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has HHLR ADVISORS, LTD.'s portfolio changed in Q4 2025?

View HHLR ADVISORS, LTD.'s latest portfolio changes, new positions, and exits for Q4 2025 on HoldingsIntel.

What is HHLR ADVISORS, LTD.'s investment strategy?

HHLR ADVISORS, LTD. is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

HHLR ADVISORS, LTD. Holdings Q4 2025 - Portfolio & Conviction Scores | HoldingsIntel

HHLR ADVISORS, LTD.

Institutional investor · Portfolio as of Q4 2025

Below Average(2.0 / 5.0)

$3.1B

AUM

Positions

New

Q4 2025

Filing Period

Quarterly Portfolio Change

SEC EDGAR SourceSEC Filings

HHLR ADVISORS, LTD. manages $3.1B across 33 positions as of Q4 2025. Top holdings: PDD (39.2%), BABA (25.6%), ONC (10.1%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.

Q4 2025 Summary

Active quarter - 6 new positions, 6 exits, 2 increased. Top move: BABA (INCREASED, conviction 91). Portfolio: $3.1B across 33 positions.

Portfolio Allocation

Top holdings by portfolio weight

PDD39.17%

BABA25.65%

ONC10.12%

FUTU8.63%

LEGN4.19%

AVBP2.55%

BEKE2.15%

BULL1.50%

CTKB1.08%

CWAN1.06%

Other0.77%

Similar Funds

Funds with similar investing DNA

Temasek Holdings (Private) Ltd

$31B

BAKER BROS. ADVISORS LP

$17.1B

+3 more

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

MAZE4Q held

Maze Therapeutics, Inc.

Avg $11.42 · $15M est. P&L

Est. P&L

+286.87%

ONC29Q held

BeOne Medicines Ltd.

Avg $134.02 · $168.6M est. P&L

Est. P&L

+121.63%

GE8Q held

GE Aerospace

Avg $204.11 · $1.3M est. P&L

Est. P&L

+63.71%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings10 of 33

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
PDDADR PDD Holdings Inc.	10.7M	$1.2B	39.2%	—	$114.13	-11.76%	15 qtrssince 2022-Q2	Increased 77
BABAADR Alibaba Group Holding Limited	5.4M	$796M	25.6%	—	$146.94	-7.73%	15 qtrssince 2022-Q2	Increased 91
ONCADR BeOne Medicines Ltd.	1M	$314.2M	10.1%	—	$134.02	+121.63%	29 qtrssince 2018-Q4	Unchanged 0
FUTUADR Futu Holdings Limited	1.6M	$267.7M	8.6%	—	$95.17	+52.05%	7 qtrssince 2024-Q2	Decreased 0
LEGNADR Legend Biotech Corporation	6M	$130.1M	4.2%	—	$50.33	-64.51%	23 qtrssince 2020-Q2	Unchanged 0
AVBP ArriVent BioPharma, Inc.	3.9M	$79.1M	2.5%	—	$17.95	+33.40%	8 qtrssince 2024-Q1	Decreased 0
BEKEADR KE Holdings Inc	4.2M	$66.8M	2.2%	—	$21.74	-23.72%	22 qtrssince 2020-Q3	Unchanged 0
BULL Webull Corporation	6M	$46.4M	1.5%	—	$10.83	-44.97%	3 qtrssince 2025-Q2	Decreased 0
CTKB Cytek Biosciences, Inc.	6.7M	$33.6M	1.1%	—	$20.96	-78.82%	18 qtrssince 2021-Q3	Unchanged 0
CWAN Clearwater Analytics Holdings,	1.4M	$32.9M	1.1%	—	$22.00	+6.82%	3 qtrssince 2025-Q2	Unchanged 0
Showing 10 of 33 results.23 more with Pro.PROUpgrade to see all →